Tasked with persuading shoppers at an outdoor market to consider taking the AstraZeneca COVID-19 vaccine, Paris city hall employee Leo Martin was finding it a tough sell.
"Which vaccine is it?" one woman, in a green scarf, asked when Martin approached her with his pitch inviting people to get inoculated at a neighbourhood vaccination centre.
When Martin told her the shot being offered at the centre was manufactured by AstraZeneca, the woman in the green scarf shook her head and said: "No, I don't want that."
Across the European Union, opinion polls and data from government vaccination programmes indicate a widespread scepticism about the AstraZeneca vaccine, rooted in very rare cases of people who take the shot experiencing blood clots.
In response to the blood-clotting cases, Denmark stopped administering the shot, and several other EU states including France are limiting it to older people.
The EU's medicines watchdog says the benefits of taking the shot far outweigh any risks, and most EU governments encourage their citizens to take it if offered.
France is also administering vaccines produced by Pfizer and Moderna, but the batch Martin and his colleagues were offering was from AstraZeneca.
"There is definitely a reluctance with regards to AstraZeneca," Martin said in a break from handing out vaccination leaflets at the market, in the north-eastern corner of Paris.
He tries to reassure people that the risks are tiny, he said, "but there's not much we can do with people's anxiety at this point".
Nevertheless, there were takers. Among people showing up for jabs at the nearby centre was Dabo Mamadou, 70.
"I try to convince those around me," to take the vaccine, he said just after having the shot in his right shoulder.
But, he said, several people in his circle were reluctant to get the AstraZeneca shot because they had heard the news reports about the blood-clotting cases.
